Scholar Rock Holding Corporation
SRRK
Rank in Stocks
#3426
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to... Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.
Share Price
$41.58
Last synced: 2026-10-20
Market Cap
$5.06B
Change (1 day)
3.34%
Change (1 year)
47.62%
Country
US
Trade Scholar Rock Holding Corporation (SRRK)
Category
Healthcare
Revenue for Scholar Rock Holding Corporation (SRRK)
Revenue in Jun 2026 TTM: 0.00
According to Scholar Rock Holding Corporation latest financial reports the company's current revenue (TTM) is 0.00. In 2023 the company made a revenue of 0.00 a decrease compared to the revenue in the year 2022 that was $33.19M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Scholar Rock Holding Corporation from 2016 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| 2026 (TTM) | 0.00 | 0.00% |
| 2024 | 0.00 | 0.00% |
| 2023 | 0.00 | -100.00% |
| 2022 | $33.19M | 76.41% |
| 2021 | $18.82M | 22.16% |
| 2020 | $15.40M | -24.83% |
| 2019 | $20.49M | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | -100.00% |
| 2016 | $379.00K | 0.00% |
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| $12.62B | - |
US
|
|
| $2.23B | - |
US
|
|
| $15.74B | - |
AU
|
|
| - | - |
CH
|
|
| $6.02B | - |
NL
|
